Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1%
To compare the efficacy of bromfenac 0.09% and dexamethasone 0.1% in the treatment of anterior chamber inflammation after uncomplicated cataract surgery.
Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to receive dexamethasone ophthalmic suspension 0.1% or bromfenac ophthalmic solution 0.09% for 2 weeks. All patients were examined on the day before surgery and postoperatively at day 1, 3, 7, 9, 11, 14 and 30. Laser flare photometry was used to quantify anterior chamber inflammation and optical coherence tomography to measure macular thickness.
Bromfenac was as effective as dexamethasone in reducing inflammation in the anterior chamber of the eye. Laser flare increased the day after surgery and progressively decreased after starting the treatment with no statistically significant difference between dexamethasone and bromfenac at all time points. Visual acuity improved steadily after surgery in both groups. Mean macular thickness was similar in both the dexamethasone and bromfenac arms at 1 month.
Short-term therapy with topical bromfenac alone is as effective as dexamethasone in low-risk cataract surgery patients.
ClinicalTrials.gov # NCT03317847; EudraCT # 2016-004358-14.
Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy.
KeywordsCataract surgery Laser flare photometry Non-steroidal anti-inflammatory drugs Ophthalmology
The authors thank all patients for kindly participating in the study.
The study was sponsored by the Santa Maria Nuova Hospital IRCCS, Reggio Emilia, Italy, who also funded the Rapid Service Fees.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Marco Coassin, Michele De Maria, Valentina Mastrofilippo, Luca Braglia, Luca Cimino, Antonio Sartori and Luigi Fontana have nothing to declare.
Compliance with Ethics Guidelines
The study protocol was approved by the local ethics committee (Comitato Etico dell’Area Vasta Emilia Nord) and the trial was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
- 2.Shalam KV (2010-2011) Ocular pharmacotherapeutics. In: American Academy of Ophthalmology, Basic and Clinical Science Course. Fundamentals and principles of ophthalmology, p. 358.Google Scholar
- 5.Duan P, Liu Y, Li J. The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):639–49.CrossRefPubMedGoogle Scholar
- 11.Ahmed M, Stephen Foster C. Steroid therapy for ocular inflammatory disease. Focal Points Clin Modul Ophthalmol. 2006;24(7):1–7.Google Scholar
- 14.Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146(6):813.e1–818.e1.Google Scholar
- 25.Wielders LH, Lambermont VA, Schouten JS, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(968–981):e33.Google Scholar